Business trip: The new economy of therapeutic psychedelics

Matias Serebrinsky, co-founder and general partner at psychedelic treatment investment fund PsyMed Ventures, believes the next generation of psychedelic therapies offering greater efficacy without side-effects will redraw the battle lines in the war against mental illness

Matias Serebrinsky

Matias Serebrinsky is a co-founder and general partner at PsyMed Ventures, a community-focused investment fund that provides capital and support to the best and most innovative companies working in psychedelic treatment, neurotech and precision psychiatry with the goal of ending mental illness. He lives in San Francisco, California. Follow him on X. Visit psymed.ventures.

Psychedelics 2.0 can turn the tide against mental illness

If you’re reading this, you are among the first people to discover Unfiltered. It means you’re ahead of the game. And it means you are with us from the start of our journey as we guide you through the greatest era of health and wellness innovation the world has ever known. A journey we’re now on together, because we want our community of users to have their say and help us shape our editorial agenda. So thank you for joining us, for being inquisitive and for being someone who can say “I was there from the very beginning”.
Joe Warner, Editor-in-Chief, Unfiltered

Business trip: The new economy of therapeutic psychedelics

Business trip: The new economy of therapeutic psychedelics

Matias Serebrinsky

Psychedelics 2.0 can turn the tide against mental illness

Joe Warner

Sign Up to Our Newsletter